Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.

To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified nine new susceptibility loci for different EOC histotypes: six for serous EOC histotypes (3q28, 4q32.3, 8q21.11, 10q24.33, 18q11.2 and 22q12.1), two for mucinous EOC (3q22.3 and 9q31.1) and one for endometrioid EOC (5q12.3). We then performed meta-analysis on the results for high-grade serous ovarian cancer with the results from analysis of 31,448 BRCA1 and BRCA2 mutation carriers, including 3,887 mutation carriers with EOC. This identified three additional susceptibility loci at 2q13, 8q24.1 and 12q24.31. Integrated analyses of genes and regulatory biofeatures at each locus predicted candidate susceptibility genes, including OBFC1, a new candidate susceptibility gene for low-grade and borderline serous EOC

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Errors in soil maps: The need for better on-site estimates and soil map predictions

High-quality soil maps are urgently needed by diverse stakeholders, but errors in existing soil maps are often unknown, particularly in countries with limited soil surveys. To address this issue, we used field soil data to assess the accuracy of seven spatial soil databases (Digital Soil Map of the World, Namibian Soil and Terrain Digital Database, Soil and Terrain Database for Southern Africa, Harmonized World Soil Database, SoilGrids1km, SoilGrids250m, and World Inventory of Soil Property Estimates) using topsoil texture as an example soil property and Namibia as a case study area. In addition, we visually compared topsoil texture maps derived from these databases. We found that the maps showed the correct topsoil texture in only 13% to 42% of all test sites, with substantial confusion occurring among all texture categories, not just those in close proximity in the soil texture triangle. Visual comparisons of the maps moreover showed that the maps differ greatly with respect to the number, types, and spatial distribution of texture classes. The topsoil texture information provided by the maps is thus sufficiently inaccurate that it would result in significant errors in a number of applications, including irrigation system design and predictions of potential forage and crop productivity, water runoff, and soil erosion. Clearly, the use of these existing maps for policy- and decision-making is highly questionable and there is a critical need for better on-site estimates and soil map predictions. We propose that mobile apps, citizen science, and crowdsourcing can help meet this need

Errors in soil maps: The need for better on-site estimates and soil map predictions.

High-quality soil maps are urgently needed by diverse stakeholders, but errors in existing soil maps are often unknown, particularly in countries with limited soil surveys. To address this issue, we used field soil data to assess the accuracy of seven spatial soil databases (Digital Soil Map of the World, Namibian Soil and Terrain Digital Database, Soil and Terrain Database for Southern Africa, Harmonized World Soil Database, SoilGrids1km, SoilGrids250m, and World Inventory of Soil Property Estimates) using topsoil texture as an example soil property and Namibia as a case study area. In addition, we visually compared topsoil texture maps derived from these databases. We found that the maps showed the correct topsoil texture in only 13% to 42% of all test sites, with substantial confusion occurring among all texture categories, not just those in close proximity in the soil texture triangle. Visual comparisons of the maps moreover showed that the maps differ greatly with respect to the number, types, and spatial distribution of texture classes. The topsoil texture information provided by the maps is thus sufficiently inaccurate that it would result in significant errors in a number of applications, including irrigation system design and predictions of potential forage and crop productivity, water runoff, and soil erosion. Clearly, the use of these existing maps for policy- and decision-making is highly questionable and there is a critical need for better on-site estimates and soil map predictions. We propose that mobile apps, citizen science, and crowdsourcing can help meet this need

Optimisation de l'espace géographique ?

Aim: Research using clinical populations to explore the relationship between hemispheric speech lateralisation and handedness has focussed on individuals with language disorders, such as dyslexia or specific language impairment (SLI). Results from such work reveal atypical patterns of cerebral lateralisation and handedness in these groups compared to controls. There are few studies that examine this relationship in people with motor coordination impairments but without speech or reading deficits, which is a surprising omission given the prevalence of theories suggesting a common neural network underlying both functions. This study fills that gap by using an emerging imaging technique in cognitive neuroscience; functional Transcranial Doppler (fTCD) sonography, and an electronic peg moving task, to assess the relationship between speech lateralisation and motor control in participants with Developmental Coordination Disorder (DCD). Method: 12 adult control participants (5 males; aged 18-28 yrs, mean = 20yrs) and 12 adults with DCD and no other developmental/cognitive impairments (4 males; aged 18-43 yrs, mean = 25.3yrs), performed a word generation task whilst undergoing fTCD imaging to establish a hemispheric lateralisation index for speech production. DCD status was confirmed via the Adult Developmental Co-ordination Disorders /Dyspraxia Checklist (ADC) (Kirby, Edwards, Sugden & Rosenblum, 2010). All participants completed a handedness questionnaire, an electronic peg moving task to determine hand skill, a shortened version of the Raven’s Matrices non-verbal reasoning test and the phonological processing section of the York Adult Assessment Battery (YAA-R). Results: As predicted the DCD group showed a significantly reduced left lateralisation pattern for the speech production task compared to controls (mean laterality indices = 1.89 and 3.77 respectively, t(22) = -2.2, p < .05). Results from the Ravens Matrices test were equivalent across groups (t(22) = .008, p = .993) and the groups did not differ significantly on the handedness classification. Performance on the motor skill task showed a clear preference for the dominant hand across both groups (t(23) = -4.472, p < .001), however the DCD group showed significantly slower mean movement times for the non-dominant hand compared to controls (t(22) = 2.270, p < .05). Discussion: This is the first study of its kind to assess hand skill and speech lateralisation in individuals with DCD. The results reveal a reduced leftwards asymmetry for speech and a slower motor performance specific to the non-dominant hand. This fits alongside previous work showing atypical cerebral lateralisation in DCD for other cognitive processes (e.g. executive function and short term memory). The findings are clinically relevant for understanding the profile of handedness in DCD and speak to debates on theories of hemispheric specialisation and language lateralisation

Plakophilin-2 is required for transcription of genes that control calcium cycling and cardiac rhythm

Plakophilin-2 (PKP2) is a component of the desmosome and known for its role in cell-cell adhesion. Mutations in human PKP2 associate with a life-threatening arrhythmogenic cardiomyopathy, often of right ventricular predominance. Here, we use a range of state-of-the-art methods and a cardiomyocyte-specific, tamoxifen-activated, PKP2 knockout mouse to demonstrate that in addition to its role in cell adhesion, PKP2 is necessary to maintain transcription of genes that control intracellular calcium cycling. Lack of PKP2 reduces expression of Ryr2 (coding for Ryanodine Receptor 2), Ank2 (coding for Ankyrin-B), Cacna1c (coding for CaV1.2) and Trdn (coding for triadin), and protein levels of calsequestrin-2 (Casq2). These factors combined lead to disruption of intracellular calcium homeostasis and isoproterenol-induced arrhythmias that are prevented by flecainide treatment. We propose a previously unrecognized arrhythmogenic mechanism related to PKP2 expression and suggest that mutations in PKP2 in humans may cause life-threatening arrhythmias even in the absence of structural disease